BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  STADA  Arzneimittel  AG  submitted  on  28  June  2006  an  application  for  Marketing 
Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Silapo,  through  the  centralised 
procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004.  
The legal basis for this application refers to:  
Article 10(4) of Directive 2001/83/EC, as amended – relating to applications for a biosimilar 
medicinal products. 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data,  appropriate non-clinical and clinical 
data for a similar biological medicinal product. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 22 March 2004 and 15 September 2005. 
The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier.  
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur:   Harald Enzmann 
Co-Rapporteur:  
Ian Hudson 
2 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The application was received by the EMEA on 28 June 2006. 
The procedure started on 19 July 2006.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  29 
September  2006  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP 
members on 12 October 2007  
During the meeting on 13 - 16 November 2006, the CHMP agreed on the consolidated List of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 21 November 2006  
The applicant submitted the responses to the CHMP consolidated List of Questions on 11 May 
2007. 
The Rapporteur’s circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 03 July 2007 
During the CHMP meeting on 16-19 July 2007, the CHMP agreed on a list of outstanding issues 
to be addressed in writing by the applicant  
During  the  meeting  on  15-18  October  2007,  the  CHMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Silapo on 18 October 2007. The applicant provided the 
letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 17 October 
2007  
1/1 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
